Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
Authors
Afsaneh Barzi
Medical Oncology and Therapeutics, City of Hope/AccessHope, Duarte, CA
Afsaneh Barzi , Orsolya Lunacsek , Federica Pisa , Xiaoyun Pan , Helene Ostojic , Zdravko Vassilev
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 45)
DOI
10.1200/JCO.2024.42.3_suppl.45
Abstract #
45
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.
First Author: William Phillips
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age-stratified analysis.
First Author: Zdravko Vassilev
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel